Stockreport

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio, Inc.  (GOSS) 
Last gossamer bio, inc. earnings: 3/24 07:00 am Check Earnings Report
PDF - Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones -- Gos [Read more]